期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 65, 期 12, 页码 1433-1450出版社
SPRINGER
DOI: 10.1007/s00262-016-1895-5
关键词
Chimeric antigen receptor; CAR; Clinical trial; Adoptive cell therapy; T cell
资金
- Deutsche Forschungsgemeinschaft, Bonn, Germany
- Deutsche Krebshilfe, Bonn, Germany
- Deutsche Jose Carreras-Leukamie Stiftung, Munich, Germany
- Else Kroner-Fresenius Stiftung, Bad Homburg v.d.H., Germany
- Fortune Program of the Medical Faculty of the University of Cologne, Cologne, Germany
In recent years, cancer treatment involving adoptive cell therapy with chimeric antigen receptor (CAR)-modified patient's immune cells has attracted growing interest. Using gene transfer techniques, the patient's T cells are modified ex vivo with a CAR which redirects the T cells toward the cancer cells through an antibody-derived binding domain. The T cells are activated by the CAR primary signaling and costimulatory domains. Such second generation CAR T cells induced complete remission of B cell malignancies in the long-term. In this fast-moving field with a growing number of engineered T cell products, we list about 100 currently ongoing trials here that involve CAR T cells targeting hematopoietic malignancies and solid cancer. Major challenges in the further development of the therapy are briefly discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据